3 Largecap Mumbai-based Stocks to Watch for Future Multibagger Potential: Reliance, Hindustan Unilever and Sun Pharma
- October 19, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Reliance Rs 1,211.20. Hindustan Unilever Rs 1,893.80. Sun Pharma Rs 1,758.80. Market caps from Rs 4.22 lakh crore to Rs 15.91 lakh crore. Data as of 16 Oct 2026.
Quick Answer
Reliance, Hindustan Unilever and Sun Pharma are the 3 picks in this Mumbai-based stocks watchlist, with market caps between Rs 4.22 lakh crore and Rs 15.91 lakh crore. Reliance stands out for the lowest PE of the group at 18.05, while Hindustan Unilever offers the highest return on equity at 22.41%. PE ratios run from 18.05 to 34.86, so compare each one with its industry PE before investing. All figures are as of 16 October 2026.
Mumbai-based stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Reliance, Hindustan Unilever and Sun Pharma meet that test, with market caps from Rs 4.22 lakh crore to Rs 15.91 lakh crore and Reliance offering the lowest PE of the group at 18.05. Mumbai is home to India’s largest conglomerate, a leading pharma maker and the country’s biggest consumer goods company.
This list covers listed companies headquartered in Mumbai with complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening Mumbai-based stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Mumbai-based Stocks and Why Do They Attract Multibagger Interest?
Mumbai-based stocks are shares of companies headquartered in India’s financial capital. They include an energy and retail conglomerate, a global pharma company and a household goods leader.
Each is a market leader in its field, with a wide customer base and strong cash flows. Companies with steady growth, strong brands and regular dividends are the ones investors compare in Mumbai-based stocks.
Mumbai-based Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 16 October 2026. Reliance has the lowest PE of the group at 18.05, while Hindustan Unilever posts the highest return on equity at 22.41%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Reliance Industries | 1,211.20 | 15,91,358 | 18.05 | 15.11 | 8.94% | 0.44 | 1,152.20 to 1,611.80 |
| Hindustan Unilever | 1,893.80 | 4,45,717 | 29.77 | 34.68 | 22.41% | 0.03 | 1,814.40 to 2,667.20 |
| Sun Pharmaceutical Industries | 1,758.80 | 4,22,427 | 34.86 | 36.42 | 13.74% | 0.06 | 1,583.70 to 2,046.90 |
Reliance: Profit Compounding at 9.63% a Year
Reliance Industries spans oil-to-chemicals, retail, digital services through Jio and a growing new energy business. It reported FY26 revenue of Rs 10,86,181 crore, up 10.53% year on year, and net profit of Rs 95,610 crore, up 18.35%. Net profit has compounded at 9.63% a year since FY22, while revenue has grown 11.18% a year. Operating margin was 17.68% in FY26. The debt-to-equity ratio is 0.44.
Revenue for the June 2026 quarter rose 20.26% to Rs 3,46,807 crore, at an operating margin of 15.89%. Domestic institutions raised their holding from 19.80% in June 2025 to 21.19% in June 2026. The stock trades at a PE of 18.05 against an industry PE of 15.11.
Hindustan Unilever: Return on Equity of 22.41%
Hindustan Unilever is India’s largest FMCG company, with brands across home care, beauty and personal care, and foods. It reported FY26 revenue of Rs 65,219 crore, up 1.69% year on year, and net profit of Rs 10,652 crore. Revenue has compounded at 5.47% a year since FY22. Operating margin was 24.49% in FY26. The debt-to-equity ratio is 0.03, which keeps interest costs low.
The stock trades at a PE of 29.77 against an industry PE of 34.68, below the sector average, with a return on equity of 22.41%. The dividend yield is 2.16%. Revenue for the June 2026 quarter rose 9.84% to Rs 17,529 crore, at an operating margin of 23.63%. Domestic institutions raised their holding from 16.07% in June 2025 to 16.99% in June 2026.
Sun Pharma: 35.75% Profit CAGR Since FY22
Sun Pharmaceutical Industries is one of India’s largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.
In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 34.86 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.
Mumbai-based Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these Mumbai-based stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | 4-Year Net Profit CAGR | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Reliance | 10,86,181 | 95,610 | 10.53% | 11.18% | 9.63% | 15.89% |
| Hindustan Unilever | 65,219 | 10,652 | 1.69% | 5.47% | 4.63% | 23.63% |
| Sun Pharma | 61,673.94 | 11,564.52 | 12.69% | 11.62% | 35.75% | 32.52% |
Check the Univest Screener for live data on these Mumbai-based stocks
Institutional Holding in Reliance, Hindustan Unilever and Sun Pharma
Institutional holding shows who is backing these Mumbai-based stocks alongside the promoter. The table uses the latest reported quarter for each. Reliance has the deepest institutional backing, with FII and DII together holding 38.39% as of June 2026. Domestic institutions increased their holding over the past year in Reliance (from 19.80% to 21.19%), Hindustan Unilever (from 16.07% to 16.99%) and Sun Pharma (from 20.23% to 22.27%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Reliance | 50.48% | 17.20% | 21.19% | 11.13% | June 2026 |
| Hindustan Unilever | 61.90% | 9.50% | 16.99% | 11.61% | June 2026 |
| Sun Pharma | 52.68% | 14.36% | 22.27% | 10.70% | September 2026 |
Risks to Weigh in Mumbai-based Stocks
Being careful with Mumbai-based stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Each company follows its own cycle, from energy prices to drug pricing.
- Large caps can move slowly in strong markets.
- Valuation: Reliance trades at a PE of 18.05 against an industry PE of 15.11, so earnings need to keep growing to support the price.
- Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Mumbai-based Stocks
Picking from Mumbai-based stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (15.11 to 36.42) and ask whether the growth rate justifies any gap.
- Track revenue growth, the operating margin and the dividend payout in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Reliance, Hindustan Unilever and Sun Pharma live prices.
Conclusion
Among Mumbai-based stocks, Reliance stands out for the lowest PE of the group at 18.05, Hindustan Unilever for the highest return on equity at 22.41% and Sun Pharma for the fastest profit growth, 35.75% a year since FY22. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing Mumbai-based stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Mumbai-based Stocks to Watch
Which are the best Mumbai-based stocks to watch for multibagger potential?
Ans. Reliance, Hindustan Unilever and Sun Pharma are the 3 names this list highlights, with market caps of Rs 15,91,358 crore, Rs 4,45,717 crore and Rs 4,22,427 crore respectively. Reliance is notable for the lowest PE of the group at 18.05. Hindustan Unilever stands out for the highest return on equity at 22.41%. Sun Pharma offers the fastest profit growth, 35.75% a year since FY22. These are watchlist names for Mumbai-based stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Hindustan Unilever a good stock for long-term investors?
Ans. Hindustan Unilever has a return on equity of 22.41%, a PE of 29.77 against an industry PE of 34.68 and a market cap of Rs 4,45,717 crore. FY26 revenue rose 1.69%, and June 2026 quarter revenue grew 9.84%. Long-term returns in Mumbai-based stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Sun Pharma become a multibagger from here?
Ans. Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Mumbai-based stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 34.86 against an industry PE of 36.42, valuation should be checked against that growth before investing.
What is the market cap of Reliance, Hindustan Unilever and Sun Pharma?
Ans. As of 16 October 2026, Reliance has a market cap of Rs 15,91,358 crore, Hindustan Unilever has a market cap of Rs 4,45,717 crore and Sun Pharma has a market cap of Rs 4,22,427 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Mumbai-based stocks.
What are the risks of investing in Mumbai-based stocks?
Ans. The main risks are commodity price swings, export drug pricing and consumer demand. Companies with varied businesses and strong brands handle these better. Reliance trades at a PE of 18.05 against an industry PE of 15.11, so earnings growth needs to hold up.
Is Reliance trading below its industry PE?
Ans. Reliance trades at a PE of 18.05 against an industry PE of 15.11. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (net profit has compounded at 9.63% a year since FY22 and FY26 revenue rose 10.53%) and balance sheet strength before drawing a conclusion.
How much do institutions hold in Reliance, Hindustan Unilever and Sun Pharma?
Ans. As of the latest reported quarter, FII and DII together hold 38.39% of Reliance (17.20% and 21.19%), 26.49% of Hindustan Unilever (9.50% and 16.99%) and 36.63% of Sun Pharma (14.36% and 22.27%). Rising institutional holding is a useful signal in Mumbai-based stocks, though it should be read with earnings trends rather than on its own.
